Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec names new chief strategy officer

Biogen Idec names new chief strategy officer

11th April 2014

Biogen Idec has announced the appointment of Dr Adam Koppel as its new senior vice-president and chief strategy officer, effective as of May 15th 2014.

Dr Koppel will join Biogen Idec from Brookside Capital, the public equity affiliate of Bain Capital, where he has worked since 2003. He has served as a managing director for the company since 2009.

In his new role, he will be responsible for leading corporate strategy and portfolio management, as well as ensuring that Biogen Idec's disease strategies clearly align with its overall corporate strategy.

The new chief strategy officer has experience as a physician, scientist and executive and joins the company at a time when it is growing in terms of size and complexity.

Dr George Scangos, chief executive officer of Biogen Idec, said: "Adam is a respected biotechnology investor and industry leader and we are thrilled to have his insight and vision to help guide our company and management team."

Earlier this year, the firm also confirmed that chairman William Young will be retiring from the board of directors after its annual meeting of stockholders, with Dr Stelios Papadopoulos confirmed as his successor.ADNFCR-8000103-ID-801711883-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.